Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (NYSE American: MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2025
Event: Entry into a Material Definitive Agreement for a private placement of Series C Convertible Preferred Stock and Warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Total Offering Size: 3,300 shares of Series C Convertible Preferred Stock with a stated value of $1,000 per share (Total potential gross proceeds: $3.3 million).
- Initial Closing Proceeds: $1.65 million received on February 13, 2025, from the sale of 1,650 shares of Preferred Stock.
- Second Closing Proceeds: $1.65 million contingent upon shareholder approval, involving the remaining 1,650 shares.
- Warrants Issued: Warrants to purchase up to 200% of the initial conversion shares (11,262,808 shares total potential).
- Transaction Expenses: Company agreed to reimburse purchasers up to $300,000, with at least $150,000 payable at the Initial Closing.
Note: The filing does not provide current revenue, profit, cash flow, or debt levels. Investors should refer to the most recent Form 10-K or 10-Q for operational financials.
Material Changes and Terms
The transaction introduces significant changes to the company's capital structure and governance:
- Conversion Terms: Preferred Stock converts to Common Stock at a price of $0.586 per share following shareholder approval. If approval is not obtained, conversion is capped at 19.99% of outstanding shares (1,016,888 shares).
- Warrant Terms: Warrants are exercisable at $0.6446 per share (110% of conversion price) and expire five years after shareholder approval. They are subject to a "call" feature if the 5-day VWAP exceeds 300% of the exercise price.
- Voting Rights: Upon shareholder approval, Preferred Stock votes on an as-converted basis. Without approval, voting is capped at the 19.99% limit.
- Lock-Up: The Company is prohibited from issuing new Common Stock or equivalents for nine months from the Initial Closing, subject to exceptions.
- Registration: The Company must file a registration statement for resale of underlying shares within 15 days of filing its 2024 Form 10-K.
Guidance, Outlook, and Governance Changes
Shareholder Approval Requirement: The Company must obtain shareholder approval by April 10, 2025. If not obtained at the first meeting, the Company must call a meeting every four months until approval is granted or the securities are no longer outstanding.
Board Appointment: Dr. Robin Smith was appointed to the Board of Directors effective the Initial Closing. She will serve on the Audit and Nominating and Corporate Governance Committees. She is considered independent and an "audit committee financial expert."
Future Director Nomination: Purchasers gain the right to nominate one additional director upon the Second Closing, provided they hold at least 30% of outstanding shares on a fully diluted basis.
Risks and Contingencies: The full $3.3 million raise is contingent on shareholder approval. Failure to obtain approval limits the conversion and exercise of warrants to the 19.99% cap.
Investor Verification Checklist
- Verify the date and outcome of the shareholder meeting scheduled to approve the issuance of Preferred Stock and Warrants (deadline: April 10, 2025).
- Confirm the dilution impact of the 11,262,808 potential warrant shares and 5,631,404 initial conversion shares on existing shareholders.
- Review the Company's cash position in the most recent 10-Q to assess the immediate impact of the $1.65 million initial proceeds.
- Monitor the filing of the registration statement for resale of the underlying common stock, required within 15 days of the 2024 10-K filing.
- Check for any subsequent filings regarding the retirement of Mr. Conrad mentioned in the press release.